Sulbactam treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus–Acinetobacter baumannii complex

References

• Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, et al. Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 2002;8:827–32.
   PubMed Web of Science ®Google Scholar
• Playford EG, Craig JC, Iredell JR. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: risk factors for acquisition, infection and their consequences. J Hosp Infect 2007;65:204–11.
   PubMed Web of Science ®Google Scholar
• Sunenshine RH, Wright MO, Maragakis LL, Harris AD, Song X, Hebden J, et al. Multidrug-resistant Acinetobacter infection mortality rate and length of hospitalization. Emerg Infect Dis 2007;13:97–103.
   PubMed Web of Science ®Google Scholar
• Ye JJ, Huang CT, Shie SS, Huang PY, Su LH, Chiu CH, et al. Multidrug resistant Acinetobacter baumannii: risk factors for appearance of imipenem resistant strains on patients formerly with susceptible strains. PLoS One 2010;5(4):e9947.
   PubMedGoogle Scholar
• Betrosian AP, Frantzeskaki F, Xanthaki A, Georgiadis G. High-dose ampicillin–sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis 2007;39:38–43.
   PubMed Web of Science ®Google Scholar
• Wood GC, Hanes SD, Croce MA, Fabian TC, Boucher BA. Comparison of ampicillin–sulbactam and imipenem–cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 2002;34:1425–30.
   PubMed Web of Science ®Google Scholar
• Levin AS, Levy CE, Manrique AE, Medeiros EA, Costa SF. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 2003;21:58–62.
   PubMed Web of Science ®Google Scholar
• Curcio D, Fernández F, Vergara J, Vazquez W, Luna CM. Late onset ventilator-associated pneumonia due to multidrug-resistant Acinetobacter spp.: experience with tigecycline. J Chemother 2009;21:58–62.
   PubMed Web of Science ®Google Scholar
• Ye JJ, Lin HS, Kuo AJ, Leu HS, Chiang PC, Huang CT, et al. The clinical implication and prognostic predictors of tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii. J Infect 2011;63:351–61.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Ortiz-Leyba C, Jiménez-Jiménez FJ, Barrero-Almodóvar AE, García-Garmendia JL, Bernabeu-Wittell M, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003;36:1111–8.
   PubMed Web of Science ®Google Scholar
• Corbella X, Ariza J, Ardanuy C, Vuelta M, Tubau F, Soro M, et al. Efficacy of sulbactam alone and in combination with ampicillin in nosocomial infections caused by multiresistant Acinetobacter baumannii. J Antimicrob Chemother 1998; 42:793–802.
   PubMed Web of Science ®Google Scholar
• Brauers J, Frank U, Kresken M, Rodloff AC, Seifert H. Activities of various beta-lactams and beta-lactam/beta-lactamase inhibitor combinations against Acinetobacter baumannii and Acinetobacter DNA group 3 strains. Clin Microbiol Infect 2005;11:24–30.
   PubMedGoogle Scholar
• Higgins PG, Wisplinghoff H, Stefanik D, Seifert H. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains. Antimicrob Agents Chemother 2004;48:1586–92.
   PubMed Web of Science ®Google Scholar
• Ko WC, Lee HC, Chiang SR, Yan JJ, Wu JJ, Lu CL, et al. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Acinetobacter baumannii strain. J Antimicrob Chemother 2004;53:393–5.
   PubMed Web of Science ®Google Scholar
• Kiffer CR, Sampaio JL, Sinto S, Oplustil CP, Koga PC, Arruda AC, et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii. Diagn Microbiol Infect Dis 2005;52:317–22.
   PubMed Web of Science ®Google Scholar
• Sader HS, Jones RN. Comprehensive in vitro evaluation of cefepime combined with aztreonam or ampicillin/sulbactam against multi-drug resistant Pseudomonas aeruginosa and Acinetobacter spp. Int J Antimicrob Agents 2005;25:380–4.
   PubMed Web of Science ®Google Scholar
• Lee NY, Wang CL, Chuang YC, Yu WL, Lee HC, Chang CM, et al. Combination carbapenem–sulbactam therapy for critically ill patients with multidrug-resistant Acinetobacter baumannii bacteremia: four case reports and an in vitro combination synergy study. Pharmacotherapy 2007;27:1506–11.
   PubMed Web of Science ®Google Scholar
• Schreckenberger PC, Daneshvar MI, Weyant RS, Hollis DG. Acinetobacter, Achromobacter, Chryseobacterium, Moraxella and other nonformentative gram-negative rods. In: Versalovic J, Carroll KC, Funke G, Jorgensen JH, Louise-Landry M, Warnock DW, editors. Manual of clinical microbiology. 10th ed. Washington, DC: American Society of Microbiology; 2011. p 714–38.
   Google Scholar
• American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005;171:388–416.
   PubMed Web of Science ®Google Scholar
• Fujitani S, Cohen-Melamed MH, Tuttle RP, Delgado E, Taira Y, Darby JM. Comparison of semi-quantitative endotracheal aspirates to quantitative non-bronchoscopic bronchoalveolar lavage in diagnosing ventilator-associated pneumonia. Respir Care 2009;54:1446–8.
   PubMedGoogle Scholar
• Man SY, Chan KM, Wong FY, Wong KY, Yim CL, Mak PS, et al. Evaluation of the performance of a modified acute physiology and chronic health evaluation (APACHE II) scoring system for critically ill patients in emergency departments in Hong Kong. Resuscitation 2007;74:259–65.
   PubMedGoogle Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, twenty-first informational supplement. CLSI document M100-S21. Wayne, PA: CLSI; 2011.
   Google Scholar
• Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006;43:43–8.
   PubMed Web of Science ®Google Scholar
• Sheng WH, Wang JT, Li SY, Lin YC, Cheng A, Chen YC, et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis 2011;70:380–6.
   PubMed Web of Science ®Google Scholar
• Wadl M, Heckenbach K, Noll I, Ziesing S, Pfister W, Beer J, et al. Increasing occurrence of multidrug-resistance in Acinetobacter baumannii isolated from four German university hospitals. Infection 2010;38:47–51.
   PubMed Web of Science ®Google Scholar
• Lee SC, Huang SS, See LC, Tsai MH, Shieh WB. In vitro activities of nine current antibiotics against culprit bacteria in nosocomial infections in an institution in northern Taiwan. Chang Gung Meg J 2011;34:580–9.
   PubMedGoogle Scholar
• Lee YC, Huang YT, Tan CK, Kuo YW, Liao CH, Lee PI, et al. Acinetobacter baumannii and Acinetobacter genospecies 13TU and 3 bacteraemia: comparison of clinical features, prognostic factors and outcomes. J Antimicrob Chemother 2011;66:1839–46.
   PubMed Web of Science ®Google Scholar